NETWORK META-ANALYSIS USING FRACTIONAL POLYNOMIALS- HEURISTIC FOR MODEL SELECTION INCORPORATING BEYOND-TRIAL EXTRAPOLATIONS (A MELANOMA EXAMPLE)
Author(s)
Goring SM1, Toor K1, Ayers D1, Chan K1, Cope S1, Johnson HM2, Moshyk A3, Kurt M4, Kotapati S3, Jansen JP5
1Precision Xtract, Vancouver, BC, Canada, 2Bristol-Myers Squibb, Uxbridge, UK, 3Bristol-Myers Squibb, Lawrenceville, NJ, USA, 4Bristol-Myers Squibb, Lawrence Township, NJ, USA, 5Precision Xtract, Oakland, CA, USA
Presentation Documents
OBJECTIVES : Fractional polynomials (FP) provide flexible parametric modeling approaches for meta-analyzing time-to-event data. Our objective was to present a model selection heuristic that improves transparency of model selection and incorporates clinical plausibility of model extrapolations. An FP-based network meta-analysis (NMA) in first-line advanced melanoma served as an example. METHODS : We fit Weibull- and Gompertz-based FP NMA models to overall survival data, with treatment effects on scale parameters (d0), representing proportional hazards. To each model, we added: 1) treatment effects on the shape (i.e. time-related) parameter (d1); 2) a second shape parameter (shape2; powers chosen from {-1, -0.5, 0, 0.5, 1}); and 3) treatment effects on shape2 (d2). These increasingly complex models were grouped into model families having the same shape parameter powers. The model selection heuristic involved ranking models according to four criteria: 1) deviance information criterion (DIC); 2) visual inspection of observed versus modeled output; 3) clinical plausibility of extrapolation periods; and 4) additional model complexity penalties. Model extrapolation periods were displayed visually by demarking the minimum follow-up time along the network path between comparators of interest. RESULTS : The top ranked model families for DIC included two Weibull-based FP model families (shape2 powers 0.5 and 0) and one Gompertz-based FP model (shape2 power -0.5). All top-ranked models matched well with observed data; however, the most complex models (having d0, d1, and d2) showed clinically implausible within-drug-class heterogeneity in the extrapolated periods. This heterogeneity was not evident in the less complex models (d0, d1) of the same model families. The model best fitting all criteria was the Weibull-based FP with shape2 power 0.5 which incorporated treatment effects d0 and d1 and involved a treatment-independent shape2 parameter. CONCLUSIONS : This model selection heuristic upholds the principle of parsimony in FP model selection, and emphasizes the importance of transparency and critical evaluation of model extrapolations.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PCN440
Topic
Methodological & Statistical Research
Topic Subcategory
Modeling and simulation
Disease
Oncology